表紙：T細胞リンパ腫治療市場 - 成長、将来展望、競合分析、2022年～2030年

市場調査レポート

商品コード

1192897

T細胞リンパ腫治療市場 - 成長、将来展望、競合分析、2022年～2030年

T-Cell Lymphoma Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

出版日: 2022年08月10日 | 発行: Acute Market Reports

| ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,500 697,995円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 6,500 1,008,215円

レポートPDFを10名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 9,000 1,395,990円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.11円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のT細胞リンパ腫治療の市場規模は、2021年に13億80万米ドルとなりました。同市場は、2022年～2030年の予測期間中に11.7%のCAGRで拡大すると予測されています。

当レポートでは、世界のT細胞リンパ腫治療市場について調査し、市場の概要とともに、タイプ別、薬剤別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

Actelion Pharmaceuticals
Spectrum Pharmaceuticals
Bristol-Myers Squibb
Shenzen ChipScreen Biosciences, Ltd.
Celgene Corporation
Eisai, Inc.
Genmab A/S
Galderma S.A.
Kyowa Hakko Kirin Co., Ltd.
Novartis AG
Neumedicines, Inc.
Amgen, Inc.
F. Hoffman La-Roche
Seattle Genetics
Soligenix, Inc.
ZIOPHARM Oncology
Medivir AB
Kura Oncology, Inc.
Aleron Therapeutics
Autolus Therapeutics plc
Innate Pharma
miRagen Therapeutics, Inc.
Trillium Therapeutics Inc.
Bellicum Pharmaceuticals, Inc.
Sorrento Therapeutics, Inc.

図表

List of Tables

TABLE 1 Global T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 2 Global T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 3 Global T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 4 Global T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 5 Global T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 6 Global T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 7 Global T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 8 North America T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 9 North America T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 10 North America T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 11 North America T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 12 North America T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 13 North America T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 14 North America T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 15 U.S. T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 16 U.S. T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 17 U.S. T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 18 U.S. T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 19 U.S. T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 20 U.S. T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 21 U.S. T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 22 Canada T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 23 Canada T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 24 Canada T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 25 Canada T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 26 Canada T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 27 Canada T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 28 Canada T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 29 Rest of North America T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 30 Rest of North America T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 31 Rest of North America T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 32 Rest of North America T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 33 Rest of North America T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 34 Rest of North America T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 35 Rest of North America T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 36 UK and European Union T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 37 UK and European Union T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 38 UK and European Union T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 39 UK and European Union T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 40 UK and European Union T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 41 UK and European Union T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 42 UK and European Union T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 43 UK T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 44 UK T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 45 UK T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 46 UK T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 47 UK T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 48 UK T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 49 UK T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 50 Germany T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 51 Germany T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 52 Germany T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 53 Germany T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 54 Germany T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 55 Germany T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 56 Germany T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 57 Spain T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 58 Spain T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 59 Spain T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 60 Spain T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 61 Spain T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 62 Spain T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 63 Spain T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 64 Italy T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 65 Italy T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 66 Italy T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 67 Italy T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 68 Italy T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 69 Italy T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 70 Italy T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 71 France T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 72 France T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 73 France T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 74 France T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 75 France T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 76 France T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 77 France T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 78 Rest of Europe T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 79 Rest of Europe T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 80 Rest of Europe T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 81 Rest of Europe T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 82 Rest of Europe T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 83 Rest of Europe T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 84 Rest of Europe T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 85 Asia T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 86 Asia T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 87 Asia T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 88 Asia T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 89 Asia T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 90 Asia T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 91 Asia T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 92 China T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 93 China T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 94 China T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 95 China T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 96 China T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 97 China T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 98 China T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 99 Japan T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 100 Japan T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 101 Japan T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 102 Japan T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 103 Japan T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 104 Japan T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 105 Japan T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 106 India T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 107 India T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 108 India T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 109 India T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 110 India T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 111 India T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 112 India T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 113 Australia T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 114 Australia T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 115 Australia T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 116 Australia T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 117 Australia T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 118 Australia T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 119 Australia T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 120 South Korea T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 121 South Korea T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 122 South Korea T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 123 South Korea T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 124 South Korea T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 125 South Korea T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 126 South Korea T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 127 Latin America T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 128 Latin America T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 129 Latin America T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 130 Latin America T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 131 Latin America T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 132 Latin America T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 133 Latin America T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 134 Brazil T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 135 Brazil T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 136 Brazil T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 137 Brazil T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 138 Brazil T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 139 Brazil T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 140 Brazil T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 141 Mexico T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 142 Mexico T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 143 Mexico T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 144 Mexico T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 145 Mexico T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 146 Mexico T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 147 Mexico T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 148 Rest of Latin America T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 149 Rest of Latin America T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 150 Rest of Latin America T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 151 Rest of Latin America T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 152 Rest of Latin America T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 153 Rest of Latin America T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 154 Rest of Latin America T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 155 Middle East and Africa T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 156 Middle East and Africa T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 157 Middle East and Africa T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 158 Middle East and Africa T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 159 Middle East and Africa T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 160 Middle East and Africa T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 161 Middle East and Africa T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 162 GCC T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 163 GCC T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 164 GCC T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 165 GCC T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 166 GCC T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 167 GCC T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 168 GCC T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 169 Africa T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 170 Africa T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 171 Africa T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 172 Africa T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 173 Africa T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 174 Africa T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 175 Africa T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)
TABLE 176 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Type, 2020-2030, USD (Million)
TABLE 177 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Drugs, 2020-2030, USD (Million)
TABLE 178 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Chemotherapy Drugs, 2020-2030, USD (Million)
TABLE 179 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Corticosteroids, 2020-2030, USD (Million)
TABLE 180 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Immunomodulators, 2020-2030, USD (Million)
TABLE 181 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Targeted Therapy Drugs, 2020-2030, USD (Million)
TABLE 182 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market By Gene Therapy Drugs, 2020-2030, USD (Million)

List of Figures

FIG. 1 Global T-Cell Lymphoma Treatment Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global T-Cell Lymphoma Treatment Market: Quality Assurance
FIG. 5 Global T-Cell Lymphoma Treatment Market, By Type, 2021
FIG. 6 Global T-Cell Lymphoma Treatment Market, By Drugs, 2021
FIG. 7 Global T-Cell Lymphoma Treatment Market, By Geography, 2021
FIG. 8 Market Geographical Opportunity Matrix - Global T-Cell Lymphoma Treatment Market, 2021
FIG. 9 Market Positioning of Key T-Cell Lymphoma Treatment Market Players, 2021
FIG. 10 Global T-Cell Lymphoma Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
FIG. 11 Global T-Cell Lymphoma Treatment Market, By Type, 2021 Vs 2030, %
FIG. 12 Global T-Cell Lymphoma Treatment Market, By Drugs, 2021 Vs 2030, %
FIG. 13 U.S. T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 14 Canada T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 15 Rest of North America T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 16 UK T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 17 Germany T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 18 Spain T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 19 Italy T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 20 France T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 21 Rest of Europe T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 22 China T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 23 Japan T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 24 India T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 25 Australia T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 26 South Korea T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 27 Rest of Asia T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 28 Brazil T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 29 Mexico T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 30 Rest of Latin America T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 31 GCC T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 32 Africa T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030
FIG. 33 Rest of Middle East and Africa T-Cell Lymphoma Treatment Market (US$ Million), 2020 - 2030

Product Code: 138504-08-22

Industry Outlook

T-cell lymphoma treatment market accounted for a market value of US$ 1300.8 Mn in 2021 and projected to grow at a CAGR of 11.7% during the forecast period from 2022 to 2030. Lymphoma is divided into two types Hodgkin's lymphoma, and non-Hodgkin's lymphoma. Non-Hodgkin's lymphoma is segmented as B-cell lymphoma and T-cell lymphoma, B-cell lymphoma accounted nearly 85% of the lymphoma diagnoses and remaining 15% being T-cell lymphoma. T-cell lymphoma is considered as the most complex lymphoma which makes it very difficult to diagnose. However, developing diagnostic technologies and incessant research and development in the field of T-cell lymphoma treatment is expected to assist the growth of this market throughout the forecast period. On 16th November 2021, FDA approved first-line treatment for peripheral T-cell lymphoma named Adcertis (brentuximab vedotin) in combination with chemotherapy for adult patients with specific types of peripheral T-cell lymphoma (PTCL). Brentuximab vedotin is a monoclonal antibody that binds to a protein (called CD30) identified on some cancer cells. Thus, such novel drug therapies entering in the T-cell lymphoma treatment market expected to drive the overall growth of the market throughout the forecast period from 2022 to 2030.

pheral T-cell lymphoma expected to be the fastest growing T-cell lymphoma treatment market"

According to Premera Blue Cross, the projected annual incidence of CTCL is 0.4 to 1 case per 100,000 (or 1,000 to 3,000 new cases per year) in the United States. However, mortality rate of CTCL is not high and patients can live with CTCL around 10 or more. The average estimated prevalence of CTCL in the U.S. is approximately 20,000. Thus, this makes CTCL most prevalent type of t-cell lymphoma providing it overall market share of 32% in T-cell lymphoma treatment market for year 2020. However, promising pipeline and recent drug approvals such as Adcertis makes PTCL one of the fastest growing T-cell lymphoma type market throughout the forecast period from 2022 to 2030.

"North America identified as the largest and fastest growing T-cell lymphoma treatment market due to introduction of novel therapies & high prevalence rate of T-cell lymphoma"

North America will maintain its dominance throughout the forecast period in T-cell lymphoma treatment market due to key driving factors such as rising prevalence & awareness related to T-cell lymphoma, promising drug pipeline & upcoming drug launches, and increasing demand for target-specific & safe drugs. According to cutaneous lymphoma foundation, CTCL is a rare disease with around 3,000 new cases recorded in the United States each year. CTCL found usually in men compared to women and specifically in patients aged above 50 years.

The key players present in the market analyzed based on product portfolio, financial information, recent market updates, and key market strategies. This report also comprises attractive investment proposition analyzed with the help of exhaustive geographical research based on PESTEL analysis. Key players profiled in the report include Actelion Pharmaceuticals, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Celgene Corporation, Seattle Genetics, Shenzen ChipScreen Biosciences, Ltd., Genmab A/S, Medivir AB, Amgen, Inc., Eisai, Inc., F. Hoffman La-Roche, and Sorrento Therapeutics, Inc., among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of T-Cell Lymphoma Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the T-Cell Lymphoma Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Type

Peripheral T-Cell Lymphoma

Anaplastic Large Cell Lymphoma

Angioimmunoblastic T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

Adult T-Cell Leukemia/Lymphoma

Others (Lymphoblastic lymphoma, Enteropathy-associated intestinal T-cell lymphoma, and Extranodal T-cell lymphoma)

Drugs

Chemotherapy Drugs

Cyclophosphamide

Doxorubicin

Vincristine

Etoposide

Gemcitabine

Pralatrexate

Navelbine

Others (Oxaliplatin, Gemcitabine, Cholormethine, Methotrexate & Mechlorethamine)

Corticosteroids

Prednisone

Dexamethasone

Immunomodulators

Lenalodimide

Interferon alfa-2b

Cyclosporine

Imiquimod

Bexarotene

Tazarotene

Forodesine (Mundesine)

Targeted Therapy Drugs

Alemtuzumab

Belinostat

Brentuximab vedotin

Romidespin

Rituximab

Mogamulizumab

Nivolumab

Gene Therapy Drugs

Yescarta (axicabtagene ciloleucel)

Kymirah (tisagenlecleucel)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of T-Cell Lymphoma Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the T-Cell Lymphoma Treatment market?

Which is the largest regional market for T-Cell Lymphoma Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving T-Cell Lymphoma Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the T-Cell Lymphoma Treatment market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global T-Cell Lymphoma Treatment Market
2.2. Global T-Cell Lymphoma Treatment Market, By Type, 2021 (US$ Million)
2.3. Global T-Cell Lymphoma Treatment Market, By Drugs, 2021 (US$ Million)
2.4. Global T-Cell Lymphoma Treatment Market, By Geography, 2021 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2021

3. T-Cell Lymphoma Treatment Market: Competitive Analysis

3.1. Market Positioning of Key T-Cell Lymphoma Treatment Market Vendors
3.2. Strategies Adopted by T-Cell Lymphoma Treatment Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. T-Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global T-Cell Lymphoma Treatment Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
- 5.3.1. Peripheral T-Cell Lymphoma
- 5.3.2. Anaplastic Large Cell Lymphoma
- 5.3.3. Angioimmunoblastic T-Cell Lymphoma
- 5.3.4. Cutaneous T-Cell Lymphoma
- 5.3.5. Adult T-Cell Leukemia/Lymphoma
- 5.3.6. Others (Lymphoblastic lymphoma, Enteropathy-associated intestinal T-cell lymphoma, and Extranodal T-cell lymphoma)

6. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
- 6.3.1. Chemotherapy Drugs
  - 6.3.1.1. Cyclophosphamide
  - 6.3.1.2. Doxorubicin
  - 6.3.1.3. Vincristine
  - 6.3.1.4. Etoposide
  - 6.3.1.5. Gemcitabine
  - 6.3.1.6. Pralatrexate
  - 6.3.1.7. Navelbine
  - 6.3.1.8. Others (Oxaliplatin, Gemcitabine, Cholormethine, Methotrexate & Mechlorethamine)
- 6.3.2. Corticosteroids
  - 6.3.2.1. Prednisone
  - 6.3.2.2. Dexamethasone
- 6.3.3. Immunomodulators
  - 6.3.3.1. Lenalodimide
  - 6.3.3.2. Interferon alfa-2b
  - 6.3.3.3. Cyclosporine
  - 6.3.3.4. Imiquimod
  - 6.3.3.5. Bexarotene
  - 6.3.3.6. Tazarotene
  - 6.3.3.7. Forodesine (Mundesine)
- 6.3.4. Targeted Therapy Drugs
  - 6.3.4.1. Alemtuzumab
  - 6.3.4.2. Belinostat
  - 6.3.4.3. Brentuximab vedotin
  - 6.3.4.4. Romidespin
  - 6.3.4.5. Rituximab
  - 6.3.4.6. Mogamulizumab
  - 6.3.4.7. Nivolumab
- 6.3.5. Gene Therapy Drugs
  - 6.3.5.1. Yescarta (axicabtagene ciloleucel)
  - 6.3.5.2. Kymirah (tisagenlecleucel)

7. North America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

7.1. Market Overview
7.2. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
7.3. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
7.4.T-Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
- 7.4.1.North America
  - 7.4.1.1. U.S.
    - 7.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 7.4.1.1.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 7.4.1.2. Canada
    - 7.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 7.4.1.2.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 7.4.1.3. Rest of North America
    - 7.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 7.4.1.3.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

8. UK and European Union T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

8.1. Market Overview
8.2. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
8.3. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
8.4.T-Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
- 8.4.1.UK and European Union
  - 8.4.1.1. UK
    - 8.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.1.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 8.4.1.2. Germany
    - 8.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.2.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 8.4.1.3. Spain
    - 8.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.3.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 8.4.1.4. Italy
    - 8.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.4.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 8.4.1.5. France
    - 8.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.5.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 8.4.1.6. Rest of Europe
    - 8.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 8.4.1.6.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

9. Asia Pacific T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

9.1. Market Overview
9.2. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
9.3. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
9.4.T-Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
- 9.4.1.Asia Pacific
  - 9.4.1.1. China
    - 9.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.1.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 9.4.1.2. Japan
    - 9.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.2.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 9.4.1.3. India
    - 9.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.3.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 9.4.1.4. Australia
    - 9.4.1.4.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.4.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 9.4.1.5. South Korea
    - 9.4.1.5.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.5.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 9.4.1.6. Rest of Asia Pacific
    - 9.4.1.6.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 9.4.1.6.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

10. Latin America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

10.1. Market Overview
10.2. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
10.3. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
10.4.T-Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
- 10.4.1.Latin America
  - 10.4.1.1. Brazil
    - 10.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 10.4.1.1.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 10.4.1.2. Mexico
    - 10.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 10.4.1.2.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 10.4.1.3. Rest of Latin America
    - 10.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 10.4.1.3.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

11. Middle East and Africa T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

11.1. Market Overview
11.2. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
11.3. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
11.4.T-Cell Lymphoma Treatment Market: By Region, 2020-2030, USD (Million)
- 11.4.1.Middle East and Africa
  - 11.4.1.1. GCC
    - 11.4.1.1.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 11.4.1.1.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 11.4.1.2. Africa
    - 11.4.1.2.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 11.4.1.2.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)
  - 11.4.1.3. Rest of Middle East and Africa
    - 11.4.1.3.1. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)
    - 11.4.1.3.1. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

12. Company Profile

12.1. Actelion Pharmaceuticals
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Portfolio
- 12.1.4. Strategic Initiatives
12.2. Spectrum Pharmaceuticals
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Portfolio
- 12.2.4. Strategic Initiatives
12.3. Bristol-Myers Squibb
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Portfolio
- 12.3.4. Strategic Initiatives
12.4. Shenzen ChipScreen Biosciences, Ltd.
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Portfolio
- 12.4.4. Strategic Initiatives
12.5. Celgene Corporation
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Portfolio
- 12.5.4. Strategic Initiatives
12.6. Eisai, Inc.
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Portfolio
- 12.6.4. Strategic Initiatives
12.7. Genmab A/S
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Portfolio
- 12.7.4. Strategic Initiatives
12.8. Galderma S.A.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Portfolio
- 12.8.4. Strategic Initiatives
12.9. Kyowa Hakko Kirin Co., Ltd.
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Portfolio
- 12.9.4. Strategic Initiatives
12.10. Novartis AG
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Portfolio
- 12.10.4. Strategic Initiatives
12.11. Neumedicines, Inc.
- 12.11.1. Company Overview
- 12.11.2. Financial Performance
- 12.11.3. Product Portfolio
- 12.11.4. Strategic Initiatives
12.12. Amgen, Inc.
- 12.12.1. Company Overview
- 12.12.2. Financial Performance
- 12.12.3. Product Portfolio
- 12.12.4. Strategic Initiatives
12.13. F. Hoffman La-Roche
- 12.13.1. Company Overview
- 12.13.2. Financial Performance
- 12.13.3. Product Portfolio
- 12.13.4. Strategic Initiatives
12.14. Seattle Genetics
- 12.14.1. Company Overview
- 12.14.2. Financial Performance
- 12.14.3. Product Portfolio
- 12.14.4. Strategic Initiatives
12.15. Soligenix, Inc.
- 12.15.1. Company Overview
- 12.15.2. Financial Performance
- 12.15.3. Product Portfolio
- 12.15.4. Strategic Initiatives
12.16. ZIOPHARM Oncology
- 12.16.1. Company Overview
- 12.16.2. Financial Performance
- 12.16.3. Product Portfolio
- 12.16.4. Strategic Initiatives
12.17. Medivir AB
- 12.17.1. Company Overview
- 12.17.2. Financial Performance
- 12.17.3. Product Portfolio
- 12.17.4. Strategic Initiatives
12.18. Kura Oncology, Inc.
- 12.18.1. Company Overview
- 12.18.2. Financial Performance
- 12.18.3. Product Portfolio
- 12.18.4. Strategic Initiatives
12.19. Aleron Therapeutics
- 12.19.1. Company Overview
- 12.19.2. Financial Performance
- 12.19.3. Product Portfolio
- 12.19.4. Strategic Initiatives
12.20. Autolus Therapeutics plc
- 12.20.1. Company Overview
- 12.20.2. Financial Performance
- 12.20.3. Product Portfolio
- 12.20.4. Strategic Initiatives
12.21. Innate Pharma
- 12.21.1. Company Overview
- 12.21.2. Financial Performance
- 12.21.3. Product Portfolio
- 12.21.4. Strategic Initiatives
12.22. miRagen Therapeutics, Inc.
- 12.22.1. Company Overview
- 12.22.2. Financial Performance
- 12.22.3. Product Portfolio
- 12.22.4. Strategic Initiatives
12.23. Trillium Therapeutics Inc.
- 12.23.1. Company Overview
- 12.23.2. Financial Performance
- 12.23.3. Product Portfolio
- 12.23.4. Strategic Initiatives
12.24. Bellicum Pharmaceuticals, Inc.
- 12.24.1. Company Overview
- 12.24.2. Financial Performance
- 12.24.3. Product Portfolio
- 12.24.4. Strategic Initiatives
12.25. Sorrento Therapeutics, Inc.
- 12.25.1. Company Overview
- 12.25.2. Financial Performance
- 12.25.3. Product Portfolio
- 12.25.4. Strategic Initiatives

T細胞リンパ腫治療市場 - 成長、将来展望、競合分析、2022年～2030年

T-Cell Lymphoma Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章序文

第2章エグゼクティブサマリー

第3章 T細胞リンパ腫治療市場：競合分析

第4章 T細胞リンパ腫治療市場：マクロ分析と市場力学

第5章 T細胞リンパ腫治療市場：タイプ別、2020年～2030年、（100万米ドル）

第6章 T細胞リンパ腫治療市場：薬剤別、2020年～2030年、（100万米ドル）

第7章北米のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第8章英国およびEUのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第9章アジア太平洋のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第10章ラテンアメリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第11章中東・アフリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第12章企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. T-Cell Lymphoma Treatment Market: Competitive Analysis

4. T-Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics

5. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)

6. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

7. North America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

8. UK and European Union T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

9. Asia Pacific T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

10. Latin America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

11. Middle East and Africa T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

12. Company Profile

T細胞リンパ腫治療市場 - 成長、将来展望、競合分析、2022年～2030年

T-Cell Lymphoma Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 T細胞リンパ腫治療市場：競合分析

第4章 T細胞リンパ腫治療市場：マクロ分析と市場力学

第5章 T細胞リンパ腫治療市場：タイプ別、2020年～2030年、（100万米ドル）

第6章 T細胞リンパ腫治療市場：薬剤別、2020年～2030年、（100万米ドル）

第7章 北米のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第8章 英国およびEUのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第9章 アジア太平洋のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第10章 ラテンアメリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第11章 中東・アフリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第12章 企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. T-Cell Lymphoma Treatment Market: Competitive Analysis

4. T-Cell Lymphoma Treatment Market: Macro Analysis & Market Dynamics

5. T-Cell Lymphoma Treatment Market: By Type, 2020-2030, USD (Million)

6. T-Cell Lymphoma Treatment Market: By Drugs, 2020-2030, USD (Million)

7. North America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

8. UK and European Union T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

9. Asia Pacific T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

10. Latin America T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

11. Middle East and Africa T-Cell Lymphoma Treatment Market, 2020-2030, USD (Million)

12. Company Profile

第1章序文

第2章エグゼクティブサマリー

第7章北米のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第8章英国およびEUのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第9章アジア太平洋のT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第10章ラテンアメリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第11章中東・アフリカのT細胞リンパ腫治療市場、2020年～2030年、（100万米ドル）

第12章企業プロファイル